| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/1000-1/2000 | Human,Mouse,Rat |
| Aliases | LIR6; CD85I; LIR-6 |
| WB Predicted band size | 53 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide of human LILRA1 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3篇与LILRA1抗体相关的文献及其摘要概括：
1. **"LILRA1 modulates macrophage-mediated inflammatory responses by regulating ITIM-dependent signaling"**
- **作者**: Jones et al. (2018)
- **摘要**: 本研究利用抗LILRA1单克隆抗体，揭示了该受体通过ITIM结构域抑制巨噬细胞中TLR触发的促炎因子释放，提示其在免疫稳态中的调控作用。
2. **"LILRA1 expression in autoimmune diseases and its interaction with HLA class I molecules"**
- **作者**: Zhang et al. (2020)
- **摘要**: 通过流式细胞术和抗LILRA1抗体检测，发现类风湿性关节炎患者单核细胞表面LILRA1表达上调，且与特定HLA-I分子结合可能参与自身免疫病理。
3. **"Antibody-mediated blockade of LILRA1 ameliorates neuroinflammation in a murine multiple sclerosis model"**
- **作者**: Brown et al. (2021)
- **摘要**: 在小鼠实验性自身免疫性脑脊髓炎模型中，抗LILRA1中和抗体通过抑制髓系细胞活化，显著减轻中枢神经系统炎症及脱髓鞘病变。
4. **"Structural characterization of LILRA1 and its antibody binding epitopes"**
- **作者**: Smith et al. (2019)
- **摘要**: 利用X射线晶体学解析LILRA1胞外结构域，并鉴定出功能性抗体结合表位，为靶向治疗药物的开发提供结构基础。
注：以上文献信息为模拟示例，实际引用需通过PubMed或SciHub等平台检索真实论文。
The leukocyte immunoglobulin-like receptor A1 (LILRA1), also known as CD85i, is a transmembrane glycoprotein belonging to the LILR family, which regulates immune cell activity by interacting with MHC class I molecules or other ligands. Expressed primarily on myeloid cells (e.g., monocytes, macrophages) and subsets of lymphocytes, LILRA1 transmits inhibitory signals through immunoreceptor tyrosine-based inhibitory motifs (ITIMs) in its cytoplasmic domain, recruiting phosphatases like SHP-1/SHP-2 to dampen cellular activation. This makes it a key player in balancing immune responses to prevent excessive inflammation or autoimmunity.
LILRA1 antibodies are critical tools for studying its function and expression in health and disease. They enable detection of LILRA1 protein levels via techniques like flow cytometry, immunohistochemistry, or Western blot, aiding research into its role in autoimmune disorders (e.g., rheumatoid arthritis, multiple sclerosis), infectious diseases, and cancer. For instance, dysregulated LILRA1 expression has been linked to altered immune surveillance in tumors or pathological inflammation. Antibodies targeting LILRA1 may also have therapeutic potential, either by blocking inhibitory signals to enhance anti-tumor immunity or by agonizing the receptor to suppress autoimmune reactions. However, challenges remain in understanding ligand specificity and signaling nuances, necessitating further validation of antibody specificity and functional assays.
×
